Right Ventricular Outflow Tract Stenting as the First Option for Palliation of Neonates with Severe Tetralogy of Fallot

Abstract

Background: Neonates with Tetralogy of Fallot (TOF) might be prostaglandin dependent and cannot be discharged from the hospital except after complete correction or palliation. Palliation could be achieved by modified Blalock-Taussig Shunt (BTS), ductal stenting, or right ventricular outflow tract (RVOT) stenting. Objective: The objective of this study was to present our experience of palliating neonates with severe TOF who require augmentation of the pulmonary blood flow by RVOT stenting. Methods: This study was conducted on a series of patients who had RVOT stenting in PSCC-Qassim, Saudi Arabia, from August 2016 till December 2019. Cases that had RVOT stenting are included. The patient's clinical data, echocardiography, cardiac catheterization, and follow-up data were recorded. Data were analyzed using The Microsoft Excel data analysis tool. Results: During the study period, four consecutive patients with a diagnosis of TOF with significant cyanosis underwent RVOT stenting. The mean age and weight were 2.8±1.7 days and 2.9±0.1 kg respectively. All were on prostaglandin infusion before the intervention. The mean saturation before and after RVOT stenting was 63% (±11%) and 82% (±4%) respectively (p = 0.018). One patient required RVOT stent dilatation after 4 months. All patients are alive and had complete TOF repair at a median age of 6.5 months (range 6 to 12 months). The median follow-up period is 13 months. The median branch PAs diameter and Z-score before RVOT stenting and immediately before complete TOF repair were 2.8 mm (Z score: -2.5) and 5.5 mm (Z score: -0.5 to -1.16) respectively (p = 0.001). Conclusion: RVOT stenting is a reasonable alternative palliation for patients with severe TOF. The technique of stent deployment in the RVOT is challenging and requires pre-intervention planning and discussion. Using soft catheters, coronary wires, and the premounted coronary stents facilitate crossing of the RVOT and pulmonary valve and then stent deploymen